Suppr超能文献

小脑共济失调临床研究联盟(CRC-SCA)的自然史研究与生物标志物收集

The Natural History Study and Biomarker Collection of the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA).

作者信息

Lin Yicheng, Amokrane Nadia, Worley Sandie, Moore Lauren R, Rosen Andrew, Crespo Laura P, Trace Kelsey, Ashizawa Tetsuo, Billnitzer Andrew, Perlman Susan, Fisher Aaron, Bushara Khalaf, Geschwind Michael D, Dietiker Cameron, Gomez Christopher M, Padmanaban Mahesh, Opal Puneet, Akhtar Rizwan S, Paulson Henry, Srinivasan Sharan, Ferng Amy, Ferrari Frank, Onyike Chiadi U, Fishman Ann, Ying Sarah, Paul Ashley, Schmahmann Jeremy D, Stephen Christopher D, Gupta Anoopum, Lin Chih-Chun, Subramony S H, Burns Matthew, Wilmot George, Duquette Antoine, Zesiewicz Theresa, Davis Marie Y, Hamedani Ali G, Vizcarra Joaquin A, Pulst Stefan M, Primeaux Sharon, Öz Gülin, Shakkottai Vikram G, Rosenthal Liana S, Kuo Sheng-Han

机构信息

Department of Neurology, Columbia University Irving Medical Center and the New York Presbyterian Hospital, New York, NY, USA.

Initiative for Columbia Ataxia and Tremor, Columbia University Irving Medical Center, New York, NY, USA.

出版信息

Cerebellum. 2025 Jul 18;24(5):134. doi: 10.1007/s12311-025-01885-0.

Abstract

Hereditary ataxias are progressive neurodegenerative disorders primarily affecting the cerebellum. Since 2009, the Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA) has studied the natural history of common types of spinocerebellar ataxias (SCAs). The CRC-SCA is a 17-site academic collaboration supported by the National Ataxia Foundation. In 2024, the CRC-SCA expanded its scope by incorporating newly identified late-onset ataxias, including repeat expansion mutations in RFC1 and FGF14 causing Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS) and SCA27B, respectively. These ongoing efforts have enriched the understanding of disease progression and facilitated access to biofluid and neuroimaging data for biomarker discovery, setting the stage for therapeutic development in hereditary ataxias. The CRC-SCA's natural history study and biomarker collection have validated several clinical outcome assessments (COAs) to capture important aspects of hereditary ataxias. We have also developed new COAs for cognitive and patient-reported outcome measures. A key component of the study includes biofluid collection-cerebrospinal fluid, plasma, and serum-to identify molecular biomarkers for disease progression and therapeutic response. Additionally, an incorporated magnetic resonance imaging (MRI) substudy provides critical imaging biomarkers, enhancing our ability to track macro- and microstructural, chemical and functional changes in the cerebellum and relate these to clinical presentations. The comprehensive, longitudinal dataset comprising COAs, biofluid biomarkers, and neuroimaging enhances clinical trial readiness in the field and accelerates therapeutic advancements for hereditary ataxias. This review highlights the collective efforts of CRC-SCA, details the study protocol, and emphasizes the integrity and specificity of the collected data elements.

摘要

遗传性共济失调是主要影响小脑的进行性神经退行性疾病。自2009年以来,小脑共济失调临床研究联盟(CRC-SCA)一直在研究常见类型的脊髓小脑共济失调(SCA)的自然病史。CRC-SCA是一项由国家共济失调基金会支持的17个研究点的学术合作项目。2024年,CRC-SCA扩大了其研究范围,纳入了新发现的迟发性共济失调,包括分别导致伴有神经病变和前庭反射消失综合征(CANVAS)的RFC1和FGF14重复扩增突变以及SCA27B。这些持续的努力丰富了我们对疾病进展的理解,并为生物标志物发现提供了获取生物流体和神经影像数据的便利,为遗传性共济失调的治疗发展奠定了基础。CRC-SCA的自然病史研究和生物标志物收集已经验证了几种临床结局评估(COA),以捕捉遗传性共济失调的重要方面。我们还开发了用于认知和患者报告结局测量的新COA。该研究的一个关键组成部分包括收集生物流体——脑脊液、血浆和血清——以识别疾病进展和治疗反应的分子生物标志物。此外,纳入的磁共振成像(MRI)子研究提供了关键的影像生物标志物,增强了我们追踪小脑宏观和微观结构、化学和功能变化并将其与临床表现相关联的能力。包含COA、生物流体生物标志物和神经影像的全面纵向数据集提高了该领域的临床试验准备程度,并加速了遗传性共济失调的治疗进展。本综述突出了CRC-SCA的集体努力,详细介绍了研究方案,并强调了所收集数据元素的完整性和特异性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验